CCR 20th Anniversary Commentary: MAPK/ERK Pathway Inhibition in Melanoma-Kinase Inhibition Redux.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 26672083.
- Also identified by DOI 10.1158/1078-0432.CCR-14-3132 and PMC identifier 4683414.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In the January 15, 2012, issue of Clinical Cancer Research, Kirkwood and colleagues published a study comparing the MEK inhibitor selumetinib with temozolomide in unselected metastatic melanoma. Although selumetinib did not improve survival or response, most responders had BRAF-activating mutations, and selumetinib has since demonstrated efficacy in BRAF-mutant melanoma. This study laid the groundwork for the evaluation of BRAF/MEK inhibitors in BRAF-mutant melanoma.
Medical subject headings
- Antineoplastic Combined Chemotherapy Protocols
- Benzimidazoles
- Cell Proliferation
- Extracellular Signal-Regulated MAP Kinases
- Melanoma